Cholecystokinin (Pancreozymin)

A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety.

Also Known As:

Networked: 2160 relevant articles (34 outcomes, 244 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rehfeld, Jens F: 24 articles (09/2021 - 01/2002)
2.	Smith, Jill P: 12 articles (01/2021 - 12/2002)
3.	Maina, Theodosia: 11 articles (03/2022 - 10/2005)
4.	Miller, Laurence J: 10 articles (01/2021 - 02/2002)
5.	Rehfeld, J F: 9 articles (01/2018 - 06/2000)
6.	Nock, Berthold A: 8 articles (03/2022 - 10/2005)
7.	Kim, Hyeyoung: 7 articles (01/2021 - 05/2011)
8.	Konturek, S J: 7 articles (03/2007 - 02/2001)
9.	Krenning, Eric P: 6 articles (03/2022 - 07/2009)
10.	Harikumar, Kaleeckal G: 6 articles (01/2021 - 01/2005)

Related Diseases

1.	Pain (Aches) 12/01/1978 - "In this study, a positive cholecystokinin cholecystogram (CCK-GB) was defined as both reproduction of the patient's biliary tract-type pain plus one or more of various roentgen abnormalities. " 11/19/2021 - "Over the past decades, accumulating evidence has demonstrated a pivotal role of cholecystokinin type 2 receptor (CCK2R) in pain modulation. " 09/01/2018 - "In addition, patients with ejection fraction <35 per cent or pain reproducible with cholecystokinin were found to have significantly higher rates of symptom resolution as well. " 12/01/2013 - "EF, body mass index percentile (BMI %), and pain with cholecystokinin (CCK) were not predictive of ongoing pain at either follow-up periods. " 12/01/2013 - "All were symptomatic with an ejection fraction (EF) <35 % or pain with cholecystokinin administration. "
2.	Body Weight (Weight, Body) 02/14/2022 - "The aim of this review was to examine: (1) the ability of cholecystokinin (CCK) or analogues of CCK to influence satiation and changes in body weight generally and (2) the efficacy of CCK in influencing satiation and eating behaviour specifically at physiological levels of dosing. " 10/01/2001 - "The objective of this study was to examine the effects of 10% food restriction on body weight, plasma cholecystokinin (CCK) levels, and exocrine pancreatic function in male Sprague-Dawley rats. " 01/01/2016 - "We reveal that a subset of NTS neurons containing cholecystokinin (CCK(NTS)) is responsive to nutritional state and that their activation reduces appetite and body weight in mice. " 07/24/2015 - "Cholecystokinin is implicated in digestion, appetite control and body weight regulation, and may play a role in several digestive disorders. " 02/01/2015 - "Analyses were conducted to assess the in vivo digestibility, food intake, body weight evolution and cholecystokinin levels in Wistar rats. "
3.	Exocrine Pancreatic Insufficiency 06/01/1989 - "The present study was undertaken to examine the intestinal phase of cholecystokinin (CCK) secretion and gall bladder contraction in patients with severe pancreatic insufficiency. " 01/01/1997 - "A failure of cholecystokinin (CCK) release after a meal has been shown among patients with exocrine pancreatic insufficiency. " 12/01/1984 - "It has been claimed that plasma cholecystokinin (CCK) concentrations are raised in patients with pancreatic insufficiency. " 12/01/1984 - "Plasma cholecystokinin concentrations in patients with pancreatic insufficiency measured by sequence-specific radioimmunoassays." 07/01/1978 - "An increase in fasting cholecystokinin (CCK) levels has been reported in patients with pancreatic insufficiency, but the relationship of these findings to the clinical conditions has not been established. "
4.	Cholelithiasis 10/01/2016 - "In the present study, we investigated expression pattern of Cholecystokinin type A receptor (CCKAR) in relation to its commonly studied polymorphism (rs1800857, T/C) in gallstone disease (GSD) patients and controls. " 10/01/2016 - "Polymorphism and Expression Profile of Cholecystokinin Type A Receptor in Relation to Gallstone Disease Susceptibility." 06/01/1998 - "Seventy-eight patients with an abnormal GEF (< 35%) on cholecystokinin hepatobiliary scan without cholelithiasis were studied retrospectively. " 04/01/1997 - "Different pathways mediate cholecystokinin actions in cholelithiasis." 03/01/1983 - "For an equivalent dose of cholecystokinin, the gallbladder in cholelithiasis is less responsive than in normal subjects."
5.	Chronic Pancreatitis 09/01/2009 - "Cholecystokinin-stimulated endoscopic pancreatic function testing has low specificity for diagnosis of early chronic pancreatitis, likely because of correctable technical limitations or failure to exclude confounding diseases. " 05/01/2000 - "The cholecystokinin postprandial plasma levels were significantly higher in all patients with chronic pancreatitis when compared with healthy individuals, which suggests the role of cholecystokinin in the feedback control of pancreatic secretion." 05/01/2000 - "The cholecystokinin postprandial plasma levels were significantly higher in patients with chronic pancreatitis when compared with those of healthy individuals (P < 0.01). " 08/01/1999 - "Cholecystokinin (CCK) secretion may be affected in patients with chronic pancreatitis (CP), but little is known on the effect of pancreatic surgery on CCK secretion. " 08/01/1999 - "Cholecystokinin secretion in patients with chronic pancreatitis and after different types of pancreatic surgery."

Related Drugs and Biologics

1.	Secretin
2.	Hormones (Hormone)
3.	Proglumide (Milid)
4.	Glucagon-Like Peptide 1 (GLP 1)
5.	Analgesics (Analgesic Drugs)
6.	Cholecystokinin (Pancreozymin)
7.	Cholesterol
8.	Gastrins
9.	Somatostatin (Somatotropin Release-Inhibiting Factor)
10.	Peptides (Polypeptides)

Related Therapies and Procedures

1.	Cholecystectomy
2.	Intravenous Administration
3.	Parenteral Nutrition
4.	Therapeutics
5.	Intravenous Infusions